UKUK

Atlas Genetics raises £16.9m for market entry of Chlamydia-diagnostics

22.07.2011

Bristol – Atlas Genetics has raised £16.9m from a syndicate of new and existing investors led by Novartis Venture Funds, and Consort Medical plc. The series B round will be drawn down over three years to help to commercialize infectious disease tests, especially the global launch of the Velox diagnostic-kit for Chlamydia and gonorrhea. Commercial launch of the system is planned for 2012. The money will also be used for the development of other infectious disease tests and to expand the immunoassay capability of the Velox system.
Velox is a point of care-diagnostic system for a broad range of infectious diseases using either nucleic acid or immuno-assays. Atals’s CEO John Clarkson commented: “We are delighted to welcome the new investors at this time when the company’s first productn is being transferred to manufacture and the core capabilities of the sensor chemistry are being expanded.“
The new investors in this series B financing are Novartis Venture Funds, LSP (Life Sciences Partners), BB Biotech Ventures and Johnson & Johnson Development Corporation. The newly announced financing follows a £1.5 million round in February 2011 supported by Consort Medical plc and other investors. The Company has been funded previously, and continues to be supported, by YFM Equity Partners, Braveheart Investment Group, Wyvern Asset Management, the Crescent Seedcorn Fund and private investors.

UKUK

06.02.2011

Oxford – Gene therapy specialist Oxford BioMedica plc announced that it has agreed to acquire a manufacturing facility from RecipharmCobra Bio­logics, the specialist biologics division of Recipharm AB, for a purchase price of...

UKUK

06.02.2011

Brussels – UCB Group S.A. announced in late December of 2010 that it has initiated a project to build an in-house biotech microbial manufacturing capacity in Bulle (Switzerland) to secure demand for its core product Cimzia...

UKUK

06.02.2011

Cambridge/London – DNA-targeted thera­peutics specialist Spirogen Ltd. is partnering with Roche’s Genentech Inc. unit to discover and develop antibody drug conjugates (ADCs) as anticancer therapeutics using Spirogen’s...

UKUK

04.02.2011

Manchester – Children that lack certain lysosomal enzymes required to break down long sugars called glycosaminoglycans develop severe damages of cartilage, organs and brain due to the accumulation of the sugar molecules. For four...

UKUK

14.01.2011

London – AstraZeneca plc has allied with Cancer Research UK in order to conduct clinical studies of experimental cancer drug combinations. Under the terms of the agreement, the research charity will conduct early stage clinical...

Displaying results 61 to 70 out of 396

< Previous 61-70 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/6/article/atlas-genetics-raises-pound169m-for-market-entry-of-chlamydia-diagnostics.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%
  • ADDEX4.00 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%

TOP

  • SANTHERA82.95 CHF20.4%
  • LONZA101.10 CHF6.1%
  • MAGFORCE6.50 EUR5.7%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.10 EUR-24.5%
  • VITA 343.96 EUR-18.4%

TOP

  • SANTHERA82.95 CHF3758.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR195.2%

FLOP

  • CYTOS0.26 CHF-93.6%
  • MEDIGENE4.65 EUR-68.1%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 22.08.2014


Current issue

All issues

Product of the week

Products